9 July 2018 - Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.

In a statement, Vertex said it had made the “best offer in the world” to NHS England that includes Orkambi (lumacaftor/ivacaftor) as well as Kalydeco (ivacaftor) and future medicines still in development.

It also provides “budget certainty to NHS England and assurance that patients will have rapid access to advances in medicines soon to come, just like agreements made in other countries,” the firm noted.

Read Pharma Times article